NCT05553834View on ClinicalTrials.gov

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 16, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
COMBINATION_PRODUCT

Alirocumab and Cemiplimab

Combination of PCSK9 inhibitor Alirocumab 150mg SC q2weeks and PD-I inhibitor Cemiplimab 350mg IV q3 weeks

Trial Locations (2)

27705

Duke University, Durham

33612

Moffitt Cancer Center, Tampa

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Duke University

OTHER

NCT05553834 - PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung | Biotech Hunter | Biotech Hunter